Innovation Pharmaceuticals Inc (IPIX)

[frenchbroad]

From Basilea Pharmaceutica H1 2023 report today:
"Basilea is one of the few companies that are fo-
cused on the development of novel anti-infec-
tives.
Our strategy is to focus on developing urgently
needed new anti-infectives for the treatment of
severe bacterial and fungal infections. We are
planning to acquire rights to further preclinical
and clinical assets in 2023 and beyond."
Also see "Upcoming Milestones" page 18.

Brilacidin can be a good fit. We will see.
https://www.basilea.com/investor-center#c161